stage Toronto cancer treatment called a ‘lifesaver’
A metastatic cancer patient in Ontario has seen his condition stabilize after participating in a Phase 1/2 clinical trial for a new immunotherapy drug called invikafusp alfa. The treatment is being studied at Toronto’s Princess Margaret Cancer Centre as a potential breakthrough for advanced skin cancer.
Why it matters
This highlights the critical role of early-stage clinical trials in providing life-saving options for patients with terminal diagnoses.
Although most investigational drugs fail to pass clinical trials, experts view invikafusp alfa with cautious optimism.
Save New subscriber benefit! Copied to clipboard A gifted article has been claimed. Out of gifts for the month Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month. Share this article paywall-free Email Copy Link Copy article link Email Share on X Share on LinkedIn Share on Reddit Share on Whatsapp Share on BlueSky Share on Threads Joe Szostak talks with his wife Cindy at their home in Dundas, Ont. In desperation, Szostak enrolled in an early-stage clinical trial at Toronto’s Princess Margaret Cancer Centre to treat his metastatic cancer.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in